NYSE: JNJ Pharmaceuticals and MedTech
A patent cliff absorbed without margin damage, and a 2025 number that is not real
Johnson & Johnson
- Written
- Price at writing
- $266.73
- Status
- Open
Thesis
Johnson & Johnson absorbed the loss of a top-five product and a 41% decline in its sales without meaningful damage to unit economics. Gross margin moved from 70.3% to 67.9% across five years, a range of 2.4 points, while STELARA revenue fell to $6,078mm and subtracted 6.2% from worldwide operational sales growth. Oncology filled the hole, growing 22% to $25,380mm.
That is the durable fact in this business. Pricing and production economics did not deteriorate under a patent cliff, which is the event the market fears most in large pharmaceuticals. I read this as evidence that the pipeline, segment mix, and capital allocation are functioning, and I am willing to own the equity on a long horizon at a price that does not require the reported 2025 numbers to be real.
Variant view
Reported 2025 results overstate the business, and the headline improvement is an accounting reversal rather than operating progress. J&J recorded talc charges of $7.0bn in 2023 and $5.1bn in 2024, then reversed $7.0bn in 2025. That single reversal is what drives net margin after taxes from 15.8% to 28.5%, return on equity to 32.9%, and return on assets to 13.5%.
Removing the reversal puts net margin near 21% and return on equity near 24%. Return on assets loses most of its improvement, since asset turnover actually fell from 0.51 in 2023 to 0.47 in 2025. On a screen, 2025 reads as a step change in profitability. It is not one.
My variant view is that the adjusted business is the thing worth owning and the reported business is not. A 21% net margin on $94bn of revenue with gross margin holding near 68% through a patent cliff is a better fact than a 28.5% margin produced by a legal accrual reversing. The first is repeatable. The second happens once and can run the other direction.
The corollary is that anyone underwriting 2025 as the new baseline is setting up to be disappointed by 2026 comparisons that will look like deterioration and will not be.
Analysis
Comparability note
One adjustment governs everything below. When Kenvue separated in August 2023, Consumer Health moved out of J&J's ongoing results and the company recast its 2021 and 2022 income statements to exclude it. Those years show only the segments J&J kept, so the five-year income statement comparison is on a consistent basis.
Balance sheets are not. J&J recast 2022 but not 2021, because a 10-K carries only two years of balance sheet data. The 2021 balance sheet still contains Consumer Health inventory and receivables while the 2021 income statement does not. Days inventory and days receivables for 2021 are therefore not comparable, and the liquidity discussion starts from 2022.
What the company is now
Two segments. Innovative Medicine generated $60,401mm of sales at a 36.9% segment margin. MedTech generated $33,792mm at 12.2%. Capital is allocated inversely to that: MedTech carries $86,482mm of identifiable assets against Innovative Medicine's $78,057mm while producing a little over half the revenue.
The reshaping is not finished. J&J announced its intention to separate the Orthopaedics business in October 2025, which generated $9,258mm in sales that year, targeting completion within 18 to 24 months.
Customer concentration is worth noting and is getting worse. Sales to the top three wholesalers moved to 21.8%, 15.5%, and 11.1% in 2025 from 14%, 11%, and 11% in 2021. Nearly half of revenue now moves through three counterparties. Domestic sales are $53.8bn against $40.4bn international.
Cost and asset structure
Cost of products sold stayed in a narrow band of 29.7% to 32.1% of revenue, reaching the top of that range in 2025 as high-margin STELARA volume declined and MedTech absorbed tariff and currency pressure. About $4,600mm of that line is amortization of acquired intangibles rather than production cost, which matters when comparing to peers. Selling, marketing, and administration is the least variable item, drifting from 25.6% to 25.1%. Research and development is the opposite, running 19.4% in 2024 and 15.6% in 2025 on the timing of purchased research.
Against a peer set averaging 28.27% cost of goods sold and 20.94% research and development, J&J spends more on production and less on internal research than the industry.
The balance sheet is best described as an intangible assets company with factories. Goodwill and intangibles never fell below 42% of total assets and reached 49.8% in 2025. Property, plant, and equipment never exceeded 11.9%. This follows from the accounting rather than from strategy: internally developed research is expensed as incurred, so the only research that appears as an asset is research J&J bought. Intangibles rose from $37,618mm to $50,403mm and goodwill reached $48,772mm, largely from Intra-Cellular, bringing total assets to $199,210mm.
Capital allocation
The stated goal is innovation across the range of health solutions. The behavior is more specific than that: buy pipeline, underinvest in fixed assets, protect the dividend.
Acquisition spending ran $60mm in 2021, $17,652mm in 2022, zero in 2023, $15,146mm in 2024, and $17,541mm in 2025. The targets were coherent. Abiomed and Shockwave deepened cardiovascular devices, Intra-Cellular at $14.5bn added neuroscience, Halda at $3.05bn added oncology. J&J is not entering new markets so much as buying further into the ones it already chose.
Capital expenditure tells the opposite story at $4,832mm in 2025, well below the $7,503mm of depreciation and amortization recorded that year. The dividend rose for a 63rd consecutive year to $5.14 per share and buybacks climbed to $5,953mm.
Liquidity
Liquidity has weakened, and the direction is consistent. Current ratio fell from 1.35 in 2021 to 1.03 in 2025. Quick ratio fell from 1.04 to 0.69 and has been below 1.0 every year since 2022.
The 2022 deterioration is explainable. J&J funded Abiomed with short-term borrowing and loans and notes payable rose from $3,766mm to $12,771mm in one year, pushing current liabilities above current assets. Liquidity recovered in 2023 on cash received from the Kenvue separation, then deteriorated again through 2025 on $17,541mm of acquisition spending.
The more important detail is what funded it. Marketable securities fell from $17,121mm to $393mm. J&J liquidated its investment portfolio to buy pipeline. That is a real strategic choice with a real cost: the company now relies on inventory and less liquid current assets to cover short-term obligations.
Days inventory increased from 152 in 2022 to 171 in 2025, which follows from the shift toward MedTech, a business that requires more physical product on hand than pharmaceuticals. Days receivables held steady in a 61 to 67 day range.
Solvency
A benchmarking limitation applies here. RMA computes debt to worth and fixed to worth using tangible net worth, which is net worth less intangibles. J&J's tangible net worth is negative in all five years because goodwill and intangibles exceed equity, so both ratios compute negative and RMA arrays negative results separately from positive ones. J&J cannot be meaningfully benchmarked against the positive industry median on either measure. I am stating that rather than reporting a number that looks comparable and is not.
On the conventional total-equity version, liabilities to stockholders' equity looks stable at 1.44 to 1.52 across five years. That stability is misleading. Total debt increased from $33.8bn to $47.9bn, and net debt more than doubled in 2025 alone, from $12.1bn to $27.8bn, driven by $9.2bn of senior notes issued to fund Intra-Cellular and for general corporate purposes.
Times interest earned shows what the leverage ratio hides. Coverage fell from 105.80 in 2021 to 20.51 in 2023, then recovered to 34.55. Interest expense rose from $183mm to $971mm as debt grew, and pre-tax earnings fell under talc charges in 2023 and 2024. Coverage at 34.55 is still comfortable in absolute terms and roughly ten times the peer median of 3.50, but the trajectory is the point, not the level.
Profitability
Gross margin held between 67.9% and 70.3% across all five years. Operating margin held between 23.4% and 26.8%. Both survived the STELARA biosimilar entry without meaningful damage.
Everything below the operating line is distorted by talc, as set out in the variant view. Net margin after taxes reads 22.6%, 20.5%, 15.6%, 15.8%, and 28.5% across the period. Adjusted for the 2025 reversal, the 2025 figure is near 21% and return on equity near 24%.
Asset turnover rose from 0.43 in 2021 to 0.51 in 2023 and then fell to 0.47. The 2023 increase is mechanical: the Kenvue separation removed roughly $19.8bn of assets while continuing operations kept selling. The subsequent decline reflects the acquired intangibles now sitting on the balance sheet.
Peer context
Against RMA data for NAICS 325412, J&J screens poorly on liquidity and well on coverage and returns. Current ratio 1.03 against a 1.90 median. Quick ratio 0.69 against 0.80. Days inventory 171 against 99. Days receivables 67 against 37. Against that, times interest earned is 34.55 versus 3.50, and return on equity 32.9% versus 16.7%, though the equity figure carries the talc distortion.
Asset turnover of 0.47 against a 1.30 median is the cleanest expression of what J&J is. The peer set includes far smaller companies without decades of acquired goodwill on the balance sheet. J&J earns a high margin on a large and slow asset base. Most of the liquidity gap is the same story: this is a company that chose to convert a securities portfolio into pipeline.
Falsification criteria
The thesis rests on durable unit economics surviving product-level losses. The following would tell me the thesis is wrong, not that the stock is temporarily down.
- Gross margin below 65% for two consecutive fiscal years. The entire thesis is that pricing and production economics are stable. Two years below the five-year floor with room to spare is the direct refutation, not a data point.
- Oncology growth decelerating below 10% while another top product faces biosimilar entry. STELARA was absorbed because oncology grew 22%. A second cliff without a second offset means the pipeline is not replacing what it loses.
- Quick ratio below 0.60 with times interest earned falling below 15. Weakening liquidity is acceptable while coverage is strong. Both deteriorating together means the acquisition strategy is being funded past the point the balance sheet supports.
- Net new talc charges exceeding the $7.0bn reversed in 2025. I am treating the reversal as a legal outcome trending favorably. Charges exceeding it would mean I misread the direction of the liability, and the adjusted-earnings framing above would need to be rebuilt.
- Capital expenditure below depreciation and amortization for three more consecutive years. Underinvesting in fixed assets for one or two years is a choice. Sustained for five, it is harvesting.
- Orthopaedics separation abandoned or delayed beyond the stated 18 to 24 months without explanation. The separation is evidence that management still prunes. Abandonment without a stated reason would undercut the capital allocation argument.
Model
The ratios in this report were calculated in a five-year workbook built from the 10-K filings for fiscal 2021 through 2025, with a peer benchmark comparison. That workbook is not published with this report. Every ratio it produces is reproduced in full in Exhibit I below, and the benchmark set it was measured against is in Exhibit II, so the analysis can be checked against the filings without it.
Exhibit I: Johnson & Johnson, fiscal 2021 to 2025
| Ratio | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Liquidity | |||||
| Days sales in receivables | 71 | 64 | 64 | 61 | 67 |
| Days sales in inventory | 162 | 152 | 154 | 165 | 171 |
| Current ratio | 1.35 | 0.99 | 1.16 | 1.11 | 1.03 |
| Quick ratio | 1.04 | 0.65 | 0.82 | 0.78 | 0.69 |
| Solvency | |||||
| Times interest earned | 105.80 | 71.14 | 20.51 | 23.10 | 34.55 |
| Liabilities to stockholders' equity | 1.46 | 1.44 | 1.44 | 1.52 | 1.44 |
| Fixed assets to long-term liabilities | 0.30 | 0.33 | 0.38 | 0.35 | 0.36 |
| Profitability and activity | |||||
| Asset turnover | 0.43 | 0.43 | 0.51 | 0.49 | 0.47 |
| Return on total assets | 9.8% | 8.7% | 8.0% | 7.8% | 13.5% |
| Return on stockholders' equity | 24.0% | 21.3% | 19.4% | 19.7% | 32.9% |
| Gross profit margin | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Operating profit margin | 25.2% | 24.9% | 24.9% | 23.4% | 26.8% |
| Net profit margin, pre-tax | 24.4% | 24.2% | 17.7% | 18.8% | 34.6% |
| Net profit margin, after tax | 22.6% | 20.5% | 15.6% | 15.8% | 28.5% |
Ratios calculated by the author from Johnson & Johnson 10-K filings, fiscal 2021 through 2025. Ratio definitions follow RMA convention, which differs from some textbook definitions.
Exhibit II: Industry benchmark, NAICS 325412
| Ratio | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Liquidity | |||||
| Days sales in receivables | 46 | 46 | 43 | 42 | 37 |
| Days sales in inventory | 126 | 126 | 122 | 101 | 99 |
| Current ratio | 2.30 | 2.00 | 1.90 | 2.00 | 1.90 |
| Quick ratio | 1.40 | 1.20 | 1.00 | 1.00 | 0.80 |
| Solvency | |||||
| Times interest earned | 9.60 | 5.80 | 7.60 | 3.80 | 3.50 |
| Liabilities to stockholders' equity | 1.20 | 2.10 | 1.30 | 1.40 | 1.40 |
| Fixed assets to long-term liabilities | 0.42 | 0.43 | 0.46 | 0.43 | 0.36 |
| Profitability and activity | |||||
| Asset turnover | 1.10 | 1.10 | 1.40 | 1.20 | 1.30 |
| Return on total assets | 10.0% | 7.2% | 8.8% | 5.9% | 5.8% |
| Return on stockholders' equity | 29.6% | 25.7% | 18.6% | 14.3% | 16.7% |
Industry benchmark ratios from RMA Annual Statement Studies, NAICS 325412, Pharmaceutical Preparation Manufacturing, fiscal 2021 through 2025. Margin lines are not reported in the RMA arrays for this NAICS code.
Sources
- Johnson & Johnson, Form 10-K filings for fiscal years 2021 through 2025. investor.jnj.com
- RMA Annual Statement Studies, NAICS 325412, via eStatement Studies.
- Congressional Budget Office, Research and Development in the Pharmaceutical Industry, April 2021. cbo.gov
- IQVIA Institute, The Global Use of Medicines 2024: Outlook to 2028, January 2024.
- Damodaran, Margins by Sector (US), 2026, Drugs (Pharmaceutical). pages.stern.nyu.edu
- Finviz screener, healthcare sector by market capitalization, July 2026.
Position
No position in JNJ at the time of writing.
Nothing here is investment advice and no advisory relationship is created by reading it. This is a record of my own analysis and my own opinion. Positions may change without notice.
Updates
No updates yet. Corrections and developments will be appended here with their own dates. The body of this report is not edited after publication.
Source: cslresearch.com. Independent research by Cory Ligon. Not investment advice. See cslresearch.com/disclosures.html